Overview
Modeling Center of Excellence Practices to Improve the Care of Patients With Biomarker-Driven Thyroid Cancer or Non-Small-Cell Lung Cancer
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
The identification of targetable tumor-specific molecular alterations has grown rapidly, leading to the application of precision medicine in oncology. Recently, therapies targeting receptor tyrosine kinase RET (rearranged during transfection) gene alterations have been developed for the treatment of multiple malignancies, including NSCLC and thyroid cancers. Although testing for RET alterations is recommended, such testing is underutilized in clinical practice, leading to suboptimal treatment selection. Moreover, a wide variance among institutions has been found in the utilization of molecular testing procedures, stemming from several factors including delays in physician orders (vs reflex testing), collection of tissue samples that are adequate for biopsies but inadequate for molecular testing, and test turnaround time.
Therefore, education on optimal molecular testing strategies and treatment selection, and development of strategies to overcome testing challenges, are vital for improving patient care. The promise of precision medicine rests in the collaborative team of pathologists and oncologists and the integration of molecular testing to optimize treatment of patients diagnosed with NSCLC or thyroid cancer. This program will provide practical guidance for improving clinical ability to follow guideline recommendations for identifying the most appropriate molecular tests, as well increasing proficiency in applying testing results to treatment selection. In addition, through expert guidance, this program will aid you in developing strategies to overcome testing barriers and improve protocols and workflows to enhance clinical practices and improve patient outcomes.
• Identify appropriate patients and optimize treatment for RET-targeted therapy
• Develop strategies to mitigate challenges and barriers to optimizing RET testing for patients with NSCLC and thyroid cancer
Attending Pathologist and Laboratory Director, Diagnostic Molecular Pathology
Medical Director, Molecular Hematopathology
Memorial Sloan Kettering Cancer Center
New York, NY
The following financial relationships have been provided:
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. The University of Chicago and ACHL require the speaker to disclose that a product is not labeled for the use under discussion.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
